<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485702</url>
  </required_header>
  <id_info>
    <org_study_id>MELT-100-001</org_study_id>
    <nct_id>NCT04485702</nct_id>
  </id_info>
  <brief_title>Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine</brief_title>
  <official_title>A Pilot Phase 1, Randomized, Single-Dose, 6-Sequences, 3-Period, Crossover Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual Tablet) and Intravenous Midazolam or Ketamine in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melt Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melt Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative Bioavailability study testing MELT-100 (midazolam and ketamine sublingual tablet)
      and IV midazolam or ketamine in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">August 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, Single-Dose, 6-Sequence, 3-Period, Crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak plasma concentration (Tmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MELT-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg midazolam and 25mg ketamine sublingual tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2mg Intravenous midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6mg Intravenous ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>2mg IV</description>
    <arm_group_label>IV midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Injectable Product</intervention_name>
    <description>6mg IV</description>
    <arm_group_label>IV ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MELT-100</intervention_name>
    <description>midazolam 3mg and ketamine 25mg SL tablet</description>
    <arm_group_label>MELT-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject must satisfy all of the following criteria to be eligible for study
             participation:

               1. Able to understand and voluntarily consent to participation in this study, and
                  provides written informed consent before the start of any study-specific
                  procedures.

               2. Healthy adult male or female ≥55 years of age.

               3. Normally active and otherwise judged to be in good health on the basis of medical
                  history and physical examination.

               4. Has vital signs (measured sitting after a minimum 3 minutes rest) at Screening
                  within the following ranges: heart rate: 40-100 bpm; systolic blood pressure
                  (BP): 90-145 mmHg; diastolic BP: 50-95 mmHg. Out-of-range vital signs may be
                  repeated once.

               5. Has a body temperature ≤37.7 degrees C

               6. Body weight ≥55 kg

               7. Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive)

               8. Female subjects are eligible only if the following applies:

                  Surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral
                  oophorectomy), or postmenopausal (confirmed with serum FSH at Screening)

               9. Male subjects must either be surgically sterile (vasectomy at least 3 months
                  prior to first dose) or agree to use an acceptable method of birth control (see
                  Section 4.4) from Screening through EOS.

              10. Is willing and able to remain in the study unit for the entire duration of each
                  confinement period.

        Exclusion Criteria:

          -  Subjects will be excluded from study participation for any of the following:

               1. History or presence of clinically significant cardiovascular, pulmonary, hepatic,
                  renal, hematologic, gastrointestinal, endocrine, immunologic, ophthalmologic,
                  dermatologic, neurologic, oncologic, or psychiatric disease or any other
                  condition that, in the opinion of the Investigator, would jeopardize the safety
                  of the subject or the validity of the study results.

               2. Has a history of glaucoma, asthma, chronic obstructive pulmonary disease, or
                  thyroid disease.

               3. Clinically significant illnesses within 4 weeks of the administration of study
                  medication (including flu, flu-like symptoms, diarrhea, vomiting, fever, sore
                  throat) or acute illness at the time of either the pre-study medical evaluation
                  or dosing.

               4. Has been in contact with someone within the last month who has tested positive
                  for SARS-CoV-2.

               5. Clinically significant surgery within 4 weeks prior to the administration of the
                  study medication.

               6. Has participated in another clinical trial (randomized subjects only) within 30
                  days before the first dose of study medication.

               7. An active malignancy of any type, or has been diagnosed with cancer within 5
                  years prior to Screening (excluding squamous or basal cell carcinoma of the
                  skin).

               8. History or presence of allergic or adverse response to midazolam, ketamine,
                  Versed, KETALAR, or any ingredients of MELT-100 or related drugs.

               9. Use of any over-the-counter (OTC) medication (including nutritional or dietary
                  supplements, herbal preparations, or vitamins) within 7 days before the first
                  dose of study medication until the EOS without evaluation and approval by the
                  Investigator.

              10. Use of any prescription medication, except statin drugs or hormonal replacement
                  therapy, from 14 days before the first dose of study medication until the EOS
                  without evaluation and approval by the Investigator.

              11. Have had a depot injection or an implant of any drugs 3 months prior to
                  administration of study medication.

              12. Has been treated with any known drugs that are moderate or strong
                  inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates,
                  phenothiazines, cimetidine, carbamazepine) within 30 days before the first dose
                  of study medication, and that, in the Investigator's judgment, may impact subject
                  safety or the validity of the study results.

                  Specifically, the use of any drugs known to inhibit CYP2C9 and CYP3A4 enzymes
                  (examples include amiodarone, fluconazole, ketoconazole, itraconazole,
                  clarithromycin, ritonavir, erythromycin, grapefruit or orange or apple juice) or
                  any drugs that are highly protein-bound (for example, warfarin, cyclosporine,
                  amphotericin B) within 30 days prior to the first dose of study medication, and
                  that in the Investigator's judgment may impact subject safety or the validity of
                  the study results.

              13. Blood or plasma donation within 30 days before the first dose of study medication
                  until the EOS. It is recommended that blood/plasma donations not be made for at
                  least 30 days after the EOS.

              14. Has any prior history of substance abuse or treatment (including alcohol).

                    1. History of significant alcohol abuse within 6 months of Screening or any
                       indication of the regular use of more than 2 units of alcohol per day (1
                       unit = 50 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

                    2. History of use of marijuana within 3 months of Screening or drugs such as
                       cocaine, phencyclidine (PCP), within 1 year of Screening.

              15. Smoking or use of tobacco- or nicotine-containing products within 60 days before
                  the first dose of study medication until the EOS Note: Nonsmokers are preferred
                  for this study.

              16. Any food allergy, intolerance, restriction, or special diet that, in the opinion
                  of the Investigator, contraindicates the subject's participation in this study.

              17. Has been on a significantly abnormal diet during the 4 weeks preceding the first
                  dose of study medication.

              18. Consumption of beverages or foods that contain alcohol, grapefruit, poppy seeds,
                  broccoli, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or
                  caffeine/xanthine from 48 hours before the first dose of study medication until
                  the EOS. Subjects will be instructed not to consume any of the above products;
                  however, allowance for an isolated single incidental consumption may be evaluated
                  and approved by the study Investigator based on the potential for interaction
                  with the study drug.

              19. Engagement in strenuous exercise from 48 hours before the first dose of study
                  medication until the EOS.

              20. A clinically significant abnormal finding on the physical examination, medical
                  history, electrocardiogram (ECG), or clinical laboratory results at Screening.

                  Note: Laboratory test values above or below the normal range does not necessarily
                  indicate that the value is &quot;clinically significant.&quot; The determination should be
                  made at the discretion of the Investigator with consultation, when necessary,
                  with the Sponsor.

              21. Presence of active infection, mucositis, cold sores, apthous ulcers, vesicles,
                  viral lesions, local irritation/inflammation, or periodontal disease of the oral
                  cavity. In addition, evidence of piercings of the tongue or anywhere in the oral
                  cavity, history of oral cavity piercings, or history of significant dental
                  disease or braces or oral hardware.

              22. Clinically significant ECG abnormalities at Screening.

              23. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ˃1.25
                  times the upper limit of normal at Screening or Check-in for Period 1.

              24. Is a female with a positive pregnancy test result.

              25. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,
                  benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.

              26. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or
                  human immunodeficiency virus (HIV) at Screening or has been previously treated
                  for hepatitis B, hepatitis C, or HIV infection.

              27. Has poor venous access during blood sampling at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Zamora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>6157670074</phone>
    <email>ldillaha@harrowinc.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

